GREENVILLE, S.C., April 8, 2010 -- KEMET Corporation (OTCBB: KEME), a leading manufacturer of tantalum, multilayer ceramic, solid aluminum, film, paper and aluminum electrolytic capacitors, announced a fourth quarter forecast.
KEMET Corporation closed at $1.60 Wednesday, trading 281,849 shares.
KEMET Provides 4th Quarter Forecast
About KEMET
KEMET Corporation (OTCBB: KEME) applies world class service and quality to deliver industry leading, high performance capacitance solutions to its customers around the world. KEMET offers the world's most complete line of surface mount and through hole capacitor technologies across tantalum, ceramic, film, aluminum, electrolytic, and paper dielectrics. Additional information about KEMET can be found at kemet.com.
KEMET defines EBITDA as operating income (loss) before depreciation and amortization expense. KEMET defines Adjusted EBITDA as EBITDA adjusted to exclude restructuring charges, stock-based compensation expense, write down of long-lived assets, and gain/loss on disposal of fixed assets. We use EBITDA and Adjusted EBITDA to monitor and evaluate our operating performance and to facilitate internal and external comparisons of the historical operating performance of our business. EBITDA and Adjusted EBITDA are not measures of performance under GAAP, and they should not be considered as an alternative to cash flow from operating activities as a measure of liquidity or as alternatives to net income as an indicator of our operating performance or any other measure of performance derived in accordance with GAAP.
For additional small cap news, tools and tips visit http://stockprofiler.us/?action=main.market_news
-------------------------------------------
SAN DIEGO, April 8, 2010 -- Aethlon Medical (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, disclosed today that a corporate video presentation and TV interview are now available to be accessed online at...
Aethlon Medical closed at $0.33 Wednesday, trading 350,165 shares.
Aethlon Medical Discloses Corporate Video Presentation and TV Interview
About Aethlon Medical
Aethlon Medical, Inc. creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our lead product, the Hemopurifier® is the first-in-class medical device to selectively capture circulating viruses and immunosuppressive proteins prior to cell and organ infection. Human studies have documented the ability of our Hemopurifier® to reduce viral load in patients infected with Hepatitis-C virus (HCV) and the Human Immunodeficiency Virus (HIV). Our primary clinical and commercialization focus is to establish the Hemopurifier® as an adjunct therapy to enhance and prolong the benefit of traditional infectious disease drug regimens.
The Hemopurifier® is also a broad-spectrum treatment candidate against drug resistant bioterror and pandemic threats. Third party research institutes have verified the capability of the device to capture Dengue Hemorrhagic Virus, Ebola Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus, and Monkeypox Virus, which serves as a model for human Smallpox infection.
Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) was formed in October of 2009 to leverage attributes of the Hemopurifier® in the emerging exosome research field. ESI seeks to inhibit the immune cell destruction caused by exosomes secreted by solid tumors, lymphomas, and leukemia. At present, the capture of immunosuppressive exosomes secreted from ovarian cancer tumors has been demonstrated invitro. The preservation of anti-cancer immune cells would likely improve patient responsiveness to established treatment options, including immunotherapy and chemotherapy. ESI is also analyzing exosome-related opportunities to improve early cancer detection and post-surgery surveillance of tumor growth, as well as approaches to harvest exosomes for research purposes and potential reintroduction into patients afflicted with autoimmune conditions such as Rheumatoid Arthritis and Lupus.
Additional information regarding Aethlon Medical and Exosome Sciences can be accessed online at aethlonmedical.com.
For additional small cap news, tools and tips visit http://stockprofiler.us/?action=main.market_news
-------------------------------------------
StockProfiler.US Announcement!
Membership with access to enhanced stock investing tools is now FREE! Claim yours at http://stockprofiler.us/index.php?action=main.register
Stay connected with StockProfiler.US – Fan up with us on Facebook (keyword: StockProfiler.US) or follow us on Twitter at http://twitter.com/StockProfilerUS
View free small cap company videos and product reviews at our YouTube channel. Visit http://www.youtube.com/StockProfilerUS
-------------------------------------------
About StockProfiler.US:
StockProfiler.US is a media source for publicly traded small cap companies and investors to come together and discover market opportunities. Public companies can effectively broadcast their message to a targeted audience who come to StockProfiler.US seeking an advantage by discovering companies in their startup phase or ones who have yet to be discovered by the investment community.
Call us at (603) 424-4420 or email info@stockprofiler.us
-------------------------------------------
Please Note: All news contained herein has been previously issued by the companies mentioned in this release, and is the property of each company, respectively. All news is edited for content. The companies that are discussed in this opinion have not approved the statements made in this opinion.
This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.
Stock Profiler.US, LLC's News Division includes but is not limited to: http://www.stockprofiler.us, http://www.associatesfortune.com, http://www.fastmoneytalk.com, http://www.markettelegraph.com, http://www.thewallstreetleader.com, and http://www.daytradersdigest.com.
Stock Profiler.US, LLC has been compensated for services rendered; Stock Profiler.US, LLC is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter.
To view full disclaimers and terms of use, go to http://stockprofiler.us/?action=main.disclaimer
-------------------------------------------
Keywords: small cap stock, small cap news, small cap stock alerts, small cap stock updates, small cap stock news updates, small cap stock profile
Posts
No comments:
Post a Comment